RECRUITING

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Description

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.

Conditions

LymphomaMultiple MyelomaNon-Hodgkin LymphomaRelapsed Hodgkin's Disease, Adult
Talk to us

Related Conditions:

LymphomaMultiple MyelomaNon-Hodgkin LymphomaRelapsed Hodgkin's Disease, Adult

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.

Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Condition
Lymphoma
Intervention / Treatment

-

Contacts and Locations

Detroit

Karmanos Cancer Institute, Detroit, Michigan, United States, 48201

New York

Columbia University, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Following diagnoses are eligible for inclusion in the study:
  • * Relapsed/Refractory Diffuse large B cell lymphoma
  • * Relapsed/Refractory indolent or relapsed/refractory transformed indolent B cell lymphomas as consolidation after second line therapy
  • * Mantle Cell lymphoma as consolidation after first-line therapy
  • * Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse or primary refractory disease
  • 2. Patients undergoing first ASCT will be eligible for the study.
  • 3. Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed.
  • 4. Age ≥18 years
  • 5. Life expectancy of greater than 6 months.
  • 1. Previously exposure to a CD38 antibody during the last 12 months.
  • 2. Participants who are receiving any other investigational agents concurrently or received any investigational agent within the last 8 weeks.
  • 3. History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab.
  • 4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • 5. Pregnant and Lactating women
  • 6. HIV-positive status due to increased risk of infection when treated with immunosuppressive therapy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Divaya Bhutani,

Divaya Bhutani, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

2025-03